Pre-made Amatuximab benchmark antibody ( Whole mAb, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-020
Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||4f33:BA:DC:FE:HG/4f3f:BA|
|95-98% SI Structure||None|
|Companies||Eisai Co Ltd;Morphotek;National Cancer Institute (USA)|
|Conditions Discontinued||Pancreatic cancer;Solid tumours|